NBRV.F Stock Overview
A biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nabriva Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.52 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -99.00% |
| 3 Month Change | -99.50% |
| 1 Year Change | 0% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Nabriva Therapeutics to effect 1-for-25 reverse stock split
Sep 15Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta
Jul 18Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022
Apr 04
Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts
Aug 11We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation
Jul 22Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation
May 08When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?
Feb 16Nabriva Therapeutics announces proposed public offering
Dec 10Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China
Dec 07Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation
Nov 08Shareholder Returns
| NBRV.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -2.6% |
| 1Y | 0% | 3.2% | 24.5% |
Return vs Industry: NBRV.F underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: NBRV.F underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| NBRV.F volatility | |
|---|---|
| NBRV.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine NBRV.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | H. Hogan | www.nabriva.com |
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections.
Nabriva Therapeutics plc Fundamentals Summary
| NBRV.F fundamental statistics | |
|---|---|
| Market cap | US$3.00 |
| Earnings (TTM) | -US$55.05m |
| Revenue (TTM) | US$29.56m |
0.0x
P/S Ratio0.0x
P/E RatioIs NBRV.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBRV.F income statement (TTM) | |
|---|---|
| Revenue | US$29.56m |
| Cost of Revenue | US$47.66m |
| Gross Profit | -US$18.11m |
| Other Expenses | US$36.95m |
| Earnings | -US$55.05m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NBRV.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 22:54 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nabriva Therapeutics plc is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Chiara Russo | Cantor Fitzgerald & Co. |
| Kevin Kedra | G. Research, LLC |